Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Immunogenic tumors grow progressively even when heavily infiltrated by CD8+ T cells. We investigated how to rescue CD8+ T-cell function in long-established immunogenic melanomas that contained a high percentage of endogenous PD-1+ tumor-specific CD8+ T cells that were dysfunctional. Treatment with αPD-L1– and αCTLA-4–blocking antibodies did not prevent tumors from progressing rapidly. We then tested exogenous tumor-specific antigen delivery into tumors using Salmonella Typhimurium A1-R (A1-R) to increase antigen levels and generate a proinflammatory tumor microenvironment. Antigen-producing A1-R rescued the endogenous tumor-specific CD8+ T-cell response: Proliferation was induced in the lymphoid organs and effector function was recovered in the tumor. Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32% rejection of long-established immunogenic melanomas. Following treatment with antigen-producing A1-R, the majority of tumor-specific CD8+ T cells still expressed a high level of PD-1 in the tumor. Combining antigen-producing A1-R with αPD-L1-blocking antibody enhanced the expansion of tumor-specific CD8+ T cells and resulted in 80% tumor rejection. Collectively, these data show a powerful new therapeutic approach to rescue dysfunctional endogenous tumor-specific CD8+ T cells and eradicate advanced immunogenic tumors. Cancer Immunol Res; 1(2); 123–33. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“This could be especially beneficial for treating patients with larger tumor loads, since adoptive T cell therapy has shown great potential for treating large established tumors in experimental and clinical studies (18, 48, 49).”
BackgroundAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 2×
“Proliferation and effector function of these CD8+ T cells are likely impaired due to engagement of PD-1 with PD-L1 expressed by cancer cells and/or antigen-presenting cells (APCs) (11, 12).”
BackgroundMethodBlockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · cited 1×
“Typhimurium strains preferentially accumulate in murine tumors (for review see (23)) and reduce immunosuppression in the tumor and tumor-draining lymph node (24, 25).”
Background
Cited by
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Rodriguez, A. B., Peske, J. D., Woods, A. N., Leick, K. M., Mauldin, I. S., Meneveau, M. O., Young, S. J., Lindsay, R. S., Melssen, M. M., Cyranowski, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109422 · Cited by 271
Self-citation
Metadata
- Authors
- Binder, D. C., Engels, B., Arina, A., Yu, P., Slauch, J. M., Fu, Y.-X., Karrison, T., Burnette, B., Idel, C., Zhao, M., Hoffman, R. M., Munn, D. H., Rowley, D. A., & Schreiber, H.
- Venue
- Cancer Immunology Research
- Published
- 2013-08-01
- Volume
- 1
- Issue
- 2
- Pages
- 123-133
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2108712362
- Cited by
- 78
- References
- 5
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-13-0058
- The paper
- Binder, D. C., Engels, B., Arina, A., Yu, P., Slauch, J. M., Fu, Y.-X., Karrison, T., Burnette, B., Idel, C., Zhao, M., Hoffman, R. M., Munn, D. H., Rowley, D. A., & Schreiber, H. (2013). Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-13-0058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.